Functional Pharmacogenetics: Analysis Of The Functional Effect Of The IL28B Genotype On Hepatitis C Virus Infection And Treatment Response.
Funder
National Health and Medical Research Council
Funding Amount
$93,843.00
Summary
An estimated 3% of the world�s population is infected with hepatitis C virus (HCV). With low spontaneous clearance rates and often a poor response to treatment many infected individuals will develop long term complications from HCV. Recent studies have identified a genetic variant that is significantly associated with spontaneous viral clearance of HCV and response to treatment for HCV. We propose to further investigate the functional basis for the effect of this human genotype on drug response.
Mitochondrial Function And The Role Of PGC-1a In Parkinson�s Disease
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Parkinson's Disease is the second most common neurodegenerative disease in Australia. Insights into the mechanisms causing Parkinson's disease may lead to therapeutic advances. This project will examine PGC-1a, a co-factor involved in the regulation of cellular energy metabolism, and examine it's role in the development of neuro-degeneration in Parkinson's disease. We aim to provide further understanding of cellular function in Parkinson's disease, and assist in therapeutic trials in neuro-degen ....Parkinson's Disease is the second most common neurodegenerative disease in Australia. Insights into the mechanisms causing Parkinson's disease may lead to therapeutic advances. This project will examine PGC-1a, a co-factor involved in the regulation of cellular energy metabolism, and examine it's role in the development of neuro-degeneration in Parkinson's disease. We aim to provide further understanding of cellular function in Parkinson's disease, and assist in therapeutic trials in neuro-degeneration.Read moreRead less
Individualisation Of Immunosuppressant Therapy In Renal Transplant Recipients.
Funder
National Health and Medical Research Council
Funding Amount
$113,496.00
Summary
People who undergo kidney transplantation require potent anti-rejection medications. Dosing is difficult. Two people given the same drug dose can have markedly different blood drug concentrations. If drug concentrations too low, there is an increased risk of rejection. If too high, there is an increased risk of drug side effects, infections and cancer. This study aims to find out why different people need different doses and to improve dosing methods, thereby improving patient outcomes.